Andrew Tucker Kuykendall MD

PubMed

• Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
  Raajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose
  Nature Medicine. 2025-03-10
• Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.
  Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew Kuykendall, David Sallman
  Leukemia. 2025-03-01
• Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML).
  Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Seongseok Yun
  Leukemia Research. 2025-03-01

Abstracts/Posters

• Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
  Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019